Skip to main content

Table 1 Summary of efficacy in clinical trials of lenvatinib in the treatment of thyroid cancer

From: Optimal use of lenvatinib in the treatment of advanced thyroid cancer

Study [ref]

Arm

Subtype

N

PFS, months

(95% CI)

OS, months

(95% CI)

ORR

(%)

DCR

(%)

Phase II [8]

Lenvatinib

DTC

58

12.6 (9.9–16.1)

-

50

93

Phase II [9]

Lenvatinib

MTC

59

9.0 (7.0-NE)

-

36

80

Phase II (Japan) [10]

Lenvatinib

DTC

25

25.8 (18.4–NE)

31.8 (31.8–NE)

68

100

MTC

9

9.2 (1.8–NE)

12.1 (3.8–NE)

22

100

ATC

17

7.4 (1.7–12.9)

10.6 (3.8–19.8)

24

94

Phase III (general population) [2]

Lenvatinib

DTC

261

18.3 (15.1–NE)

NE

64.8

87.7

Placebo

131

3.6 (2.2–3.7)

1.5

55.7

Phase III (Japanese population) [7]

Lenvatinib

DTC

30

16.5 (7.4-NE)

NE

63.3

90.0

Placebo

10

3.7 (1.6–9.1)

0.0

60.0

  1. ATC anaplastic thyroid cancer; DCR disease control rate; DTC differentiated thyroid cancer; MTC medullary thyroid cancer; NE, not estimable; ORR overall response rate; OS overall survival; PFS progression-free survival